Mushroom-derived drug posts improved survival data in Golden Biotech’s pancreatic cancer trial

Golden Biotechnology has shared updated data on its mushroom-derived drug candidate in metastatic pancreatic cancer, linking first-line use of the molecule to median overall survival (OS) of 14.1 months.